Hypofractionated Radiotherapy for Prostate Cancer: Emerging Evidence and Clinical Practice
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 57
Special Issue Editor
Interests: prostate cancer; radiation oncology; diagnostic imaging
Special Issue Information
Dear Colleagues,
Hypofractionated radiotherapy has become a pivotal modality in the treatment of prostate cancer, offering comparable efficacy to conventional fractionation while demonstrating improved patient convenience and healthcare resource optimization. This Special Issue aims to highlight emerging clinical evidence, technological innovations, and practical applications of hypofractionated radiotherapy in prostate cancer care. Topics of interest include ultra-hypofractionation, image-guided radiotherapy, toxicity management, patient selection, and integration with systemic therapies. We welcome scholars to submit original research articles, comprehensive reviews, and expert perspectives that advance the understanding and implementation of hypofractionated approaches in clinical practice. Through this Special Issue, we hope to foster multidisciplinary dialogue and inspire future research directions.
Prof. Dr. Hiromichi Ishiyama
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hypofractionated radiotherapy
- prostate cancer
- ultra-hypofractionation
- image-guided radiotherapy (IGRT)
- toxicity and outcomes
- patient selection
- radiotherapy techniques
- combined modality therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
